Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study)

Gottlieb, A., Gnanasakthy, A., Strober, B., Zhang, J., & Tran, MH. (2014). Secukinumab’s time to psoriasis response on patient-reported psoriasis symptoms (ERASURE study). Journal of the American Academy of Dermatology, 70(5, Suppl. 1), AB189. https://doi.org/10.1016/j.jaad.2014.01.782

Abstract

Background: Secukinumab (AIN457), a fully human anti–interleukin-17A monoclonal antibody, was evaluated in a phase 3 clinical study at week 12 (vs. placebo) for efficacy and safety in subjects with moderate to severe plaque psoriasis. Time to symptom response was evaluated using the Psoriasis Symptom Diary (PSD), which measures psoriasis-related characteristics subjects have reported as important and relevant to their disease and treatment.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

The daily association between affect and alcohol use: A meta-analysis of individual participant data
Article

The use of patient experience feedback in rehabilitation quality improvement and codesign activities
Article

Protection of forest ecosystems in the eastern United States from elevated atmospheric deposition of sulfur and nitrogen
Article

SPTSSA variants alter sphingolipid synthesis and cause a complex hereditary spastic paraplegia